MapLight Therapeutics, Inc.
NASDAQ:MPLTBiotechnology
+$0.39 today
- Market cap
- $283.41M
- Beta
- 2.65
- P/E (TTM)
- -2.8
- EPS (TTM)
- -$4.41
Volume 0.42M
Average 0.73M
MPLT Long-term Investments
Investments the company intends to hold for more than a year.
MapLight Therapeutics, Inc.NASDAQ: MPLT
Long-term Investments · Q1 FY2026 · quarter ended Mar 2026
Long-term investments rises 3059.1% from a year ago
Long-term investments stood at $85.3M at the end of Q1 FY2026, up 3059.1% from a year earlier and down 42.4% from the prior quarter. Over 3 fiscal years it compounded at +758.8% a year.
Context
- Long-term investments amounted to 20.4% of total assets at the end of Q1 FY2026, up 17.9 pp from a year earlier.
- Long-term investments increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether long-term investments keeps rising in the next quarterly balance sheet after a +3059.1% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Long-term Investments history
USD · from the balance sheet
- Latest · FY2025
- 148.2M USD
- Year-over-year change
- +1179.0%
- 3-year CAGR
- +758.8%
| Period | Period end | Long-term Investments | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 148.2M | +1179.0% |
| FY2024 | 2024-12-31 | 11.59M | +849.8% |
| FY2023 | 2023-12-31 | 1.22M | +421.4% |
| FY2022 | 2022-12-31 | 234K | — |
Long-term Investments vs competitors
How MPLT compares with its peers on the latest reported figures
- MPLT's Mar 2026 long-term investments of $85.3M is the highest of the 11 companies compared; the peer median is $0.
- Its year-over-year change of +3059.1% is the highest of 5, against a peer median of +0.3%.
- Long-term investments amounts to 20.4% of total assets for MPLT, versus a peer median of 0.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $85.3M | +3059.1% | +758.8% | 20.4% | |
| Mar 2026 | $41.96M | +100.7% | +125.8% | 18.6% | |
| Mar 2026 | $36.15M | +493.4% | +33.8% | 13.0% | |
LBRXLB Pharmaceuticals Inc Common Stock | Mar 2026 | $776K | — | — | 0.2% |
DFTXDefinium Therapeutics, Inc. | Sep 2026 | $0 | — | — | 0.0% |
| Mar 2026 | $0 | -100.0% | — | 0.0% | |
RAPPRapport Therapeutics, Inc. Common Stock | Mar 2026 | $0 | — | — | 0.0% |
| Mar 2026 | $0 | -100.0% | — | 0.0% | |
| Jun 2026 | $0 | — | — | 0.0% | |
| Dec 2025 | $0 | — | — | 0.0% | |
NMRANeumora Therapeutics, Inc. Common Stock | Mar 2026 | $0 | — | — | 0.0% |
| Peer median (excluding MPLT) | $0 | +0.3% | +79.8% | 0.0% | |
Competitors are the stored peer set for MPLT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
MapLight Therapeutics, Inc.
NASDAQ:MPLT
Intrinsic Alpha fair value
Locked
Current Price
$6.65
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.